Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The trial will test if the combination of bexmarilimab and nivolumab can help patients whose cancers have stopped responding to immunotherapy treatment. It will focus on two cancers: non-small cell lung cancer and melanoma. Early research suggests bexmarilimab may change some immune cells inside the tumour so they create a stronger "attack" signal, which could help other immune cells recognise and kill cancer cells more effectively. This may make it easier for PD-1 immunotherapy drugs to work again by helping the immune system stay active against the tumour. This is a Phase I/II clinical trial. In Phase I, researchers will give increasing doses of bexmarilimab together with a standard (fixed) dose of nivolumab to patients with solid tumours, to find the safest and most suitable dose to use going forward (the recommended Phase 2 dose). In Phase II, the study will treat two groups of patients-one with non-small cell lung cancer and one with melanoma-using that selected dose.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie nowotwór, który nie reaguje na standardowe leczenie lub pacjent je odrzuca
- •Wcześniejsze leczenie systemowe (od 1 do 3 linii) dla zaawansowanego nowotworu
- •Leczenie co najmniej dwoma cyklami immunoterapii z wykazanym postępem choroby w ciągu 12 tygodni
- •Wcześniejsza korzyść z immunoterapii (ponad 6 miesięcy leczenia lub częściowa odpowiedź)
- •Spodziewana długość życia co najmniej 12 tygodni
- •Dobry stan ogólny (skala WHO 0-1)
- •Mierzalne ogniska nowotworu
- •Dla kobiet: brak ciąży i zgoda na antykoncepcję podczas badania i 6 miesięcy po
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 18, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
The Christie NHS Foundation Trust
Manchester, United Kingdom
The Royal Marsden NHS Foundation Trust - Drug Development Unit
Sutton, United Kingdom
Trial contact
Aasia Hussain, PhD
Anna Zachariou, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/12/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.